Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
RESEARCH TOOLSreports
VERV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.31 - $19.34
Previous CloseN/A
Volume257.30K
Average Volume (3M)1.60M
Market Cap
$718.37M
Enterprise Value-$59.04M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.33
Next Earnings
Feb 26, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding84,663,840
10 Day Avg. Volume1,281,336
30 Day Avg. Volume1,601,997
Standard Deviation0.26
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.45
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.37
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$31.00Price Target Upside295.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCurrent cash and equivalents provide financial runway into mid-2027, supporting the company's operations and strategic developments.
Management TeamThe company's gene editing strategy for cardiovascular disease is supported by a world-class management team, increasing the probability of success for Verve.
Safety ProfileAn acceptable VERVE-102 safety profile coupled with significant LDL-C reduction can increase investor confidence in VERVE-102 development, driving substantial upside in VERV.
Bears Say
Efficacy UncertaintyVERVE-102 efficacy is largely derisked by VERVE-101 clinical data, with an expected significant reduction in LDL-C.
Market DependencyLLY's decision on its opt-in rights is seen as a major catalyst for VERV and the entire gene editing space, reflecting potential high interest in Verve's LDL-C programs.
Trial TimelineManagement narrowed guidance on VERVE-102 Phase I initial readout to the second quarter of 2025, expected to include safety and efficacy data.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VERV FAQ
What was Verve Therapeutics’s price range in the past 12 months?
Verve Therapeutics lowest stock price was $4.30 and its highest was $19.34 in the past 12 months.
What is Verve Therapeutics’s market cap?
Verve Therapeutics’s market cap is $718.37M.
When is Verve Therapeutics’s upcoming earnings report date?
Verve Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Verve Therapeutics’s earnings last quarter?
Verve Therapeutics released its earnings results on Nov 05, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.684 by $0.094.
Is Verve Therapeutics overvalued?
According to Wall Street analysts Verve Therapeutics’s price is currently Undervalued.
Does Verve Therapeutics pay dividends?
Verve Therapeutics does not currently pay dividends.
What is Verve Therapeutics’s EPS estimate?
Verve Therapeutics’s EPS estimate is -0.68.
How many shares outstanding does Verve Therapeutics have?
Verve Therapeutics has 84,663,840 shares outstanding.
What happened to Verve Therapeutics’s price movement after its last earnings report?
Verve Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.684. Following the earnings report the stock price went up 5.455%.
Which hedge fund is a major shareholder of Verve Therapeutics?
Currently, no hedge funds are holding shares in VERV
---
Verve Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (295.91% Upside)
$31.00 (295.91% Upside)
Blogger Sentiment
Bullish
VERV Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.34%
12-Months-Change
Fundamentals
Return on Equity
-38.74%
Trailing 12-Months
Asset Growth
8.41%
Trailing 12-Months
Company Description
Verve Therapeutics
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
---
VERV Stock 12 Month Forecast
Average Price Target
$31.00
▲(295.91% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering VERV
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-21.14%
reiterated a buy rating 4 months ago
Copying Luca Issi's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -21.14% per trade.
---